A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24

Mansoor Raza Mirza, Troels K Bergmann, Morten Mau-Sørensen, René dePont Christensen, Elisabeth Åvall-Lundqvist, Michael J Birrer, Morten Jørgensen, Henrik Roed, Susanne Malander, Flemming Nielsen, Ulrik Lassen, Kim Brøsen, Line Bjørge, Johanna Mäenpää

Fingeraftryk

Dyk ned i forskningsemnerne om 'A phase I study of the PARP inhibitor niraparib in combination with bevacizumab in platinum-sensitive epithelial ovarian cancer: NSGO AVANOVA1/ENGOT-OV24'. Sammen danner de et unikt fingeraftryk.

Medicin og biovidenskab

Kemi